RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 OutlookMarket Beat·Jul 10 at 09:01 PMRXST-3.35%ALC+1.04%
RxSight: Alcon Partnership and Margin Improvements Offset Near-Term Sales Shortfall; Buy Rating and $11 Price Target ReiteratedTip Ranks·Jul 7 at 04:25 AMRXST-3.35%ALC+1.04%
RxSight shares are trading lower after the company issued Q2 and FY26 sales guidance. The company announced a non-exclusive collaboration with Alcon to jointly develop adjustable presbyopia-correcting intraocular lenses.benzinga_article·Jul 6 at 03:35 PMRXST-3.35%ALC+1.04%
RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration AgreementUnusual Whales·Jul 6 at 03:17 PMRXST-3.35%ALC+1.04%
Alcon, RxSight collaborate to develop adjustable presbyopia-correcting intraocular lensesPUBT·Jul 6 at 03:15 PMRXST-3.35%ALC+1.04%
RxSight forecasts 2026 revenue of $140 million-$160 million, cuts sales outlook to $110 million-$120 millionPUBT·Jul 6 at 03:15 PMRXST-3.35%ALC+1.04%
